Harnessing the hidden antitumor power of the MLL-AF4 oncogene to fight leukemia

Smita Matkar; Bryson W Katona; Xianxin Hua

doi:10.1016/j.ccr.2014.03.028

Harnessing the hidden antitumor power of the MLL-AF4 oncogene to fight leukemia

Cancer Cell. 2014 Apr 14;25(4):411-3. doi: 10.1016/j.ccr.2014.03.028.

Authors

Smita Matkar¹, Bryson W Katona¹, Xianxin Hua²

Affiliations

¹ Abramson Family Cancer Research Institute, Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine, 421 Curie Boulevard, Philadelphia, PA 19104, USA.
² Abramson Family Cancer Research Institute, Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine, 421 Curie Boulevard, Philadelphia, PA 19104, USA. Electronic address: huax@mail.med.upenn.edu.

Abstract

It is unclear whether the antiproliferative/proapoptotic activity of oncogenes can be pharmacologically reactivated in cancer cells. In this issue of Cancer Cell, Liu and colleagues report that a proteasome inhibitor reactivates an MLL-AF4 controlled antitumor program to kill leukemia cells in an oncogene dose- and cell type-dependent manner.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Histone-Lysine N-Methyltransferase
Humans
Myeloid-Lymphoid Leukemia Protein / metabolism*
Oncogene Proteins, Fusion / metabolism*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
Proteasome Inhibitors / pharmacology*

Substances

KMT2A protein, human
Oncogene Proteins, Fusion
Proteasome Inhibitors
Myeloid-Lymphoid Leukemia Protein
Histone-Lysine N-Methyltransferase

Abstract

Publication types

MeSH terms

Substances

Grants and funding